Cargando…
Scleroderma Patient-centered Intervention Network—Scleroderma Support group Leader EDucation (SPIN-SSLED) program: non-randomised feasibility trial
OBJECTIVES: The Scleroderma Patient-centered Intervention Network—Scleroderma Support group Leader EDucation (SPIN-SSLED) Programme was designed to improve confidence and self-efficacy and to reduce burden for support group leaders. Objectives were to (1) evaluate feasibility of programme delivery,...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858260/ https://www.ncbi.nlm.nih.gov/pubmed/31719073 http://dx.doi.org/10.1136/bmjopen-2019-029935 |
_version_ | 1783470920777596928 |
---|---|
author | Thombs, Brett D Dyas, Laura Pépin, Mia Aguila, Kylene Carrier, Marie-Eve Tao, Lydia Harb, Sami Malcarne, Vanessa L El-Baalbaki, Ghassan Peláez, Sandra Sauve, Maureen Hudson, Marie Platt, Robert W |
author_facet | Thombs, Brett D Dyas, Laura Pépin, Mia Aguila, Kylene Carrier, Marie-Eve Tao, Lydia Harb, Sami Malcarne, Vanessa L El-Baalbaki, Ghassan Peláez, Sandra Sauve, Maureen Hudson, Marie Platt, Robert W |
author_sort | Thombs, Brett D |
collection | PubMed |
description | OBJECTIVES: The Scleroderma Patient-centered Intervention Network—Scleroderma Support group Leader EDucation (SPIN-SSLED) Programme was designed to improve confidence and self-efficacy and to reduce burden for support group leaders. Objectives were to (1) evaluate feasibility of programme delivery, including required resources, management issues and scientific aspects (eg, performance of outcome measures) and (2) assess user satisfaction and identify any modifications needed to improve programme content or delivery based on participant feedback. DESIGN: Non-randomised feasibility trial. SETTING: North American patient organisations. PARTICIPANTS: Current support group leaders or potential new leaders referred by patient organisations. INTERVENTION: The programme included 13 modules delivered live via videoconference over 3 months (April to July 2018) in 60 to 90 min sessions. OUTCOME MEASURES: (1) Elements of feasibility, including enrolment and consent procedures, percentage of referred group leaders who consented to participate, session attendance and technical support requirements; (2) programme usability, understandability, organisation and clarity; (3) leader satisfaction with the programme and (4) planned trial outcome measures, including support group leader self-efficacy, burnout, emotional distress and physical function. RESULTS: All 12 referred potential participants consented to enrol, and 10 were included in two training groups of five participants each. Participants attended 95% of sessions. Required technical support was minimal, and videoconferencing technology functioned well. Overall programme satisfaction rating was 9.4/10. Mean item rating on the eight items of the Client Satisfaction Questionnaire-8 was 3.83 (1=low satisfaction; 4=high satisfaction). Pre-post scores on the Scleroderma Support Group Leader Self-efficacy Scale increased by 1.7 SDs (large effect); scores on burnout, emotional distress and physical function improved by 0.44, 0.38 and 0.45 SDs (moderate effects). CONCLUSION: The SPIN-SSLED Programme was feasibly delivered, including management, resource and scientific aspects. Participant satisfaction was high. The programme is ready to be tested in a full-scale randomised controlled trial. TRIAL REGISTRATION NUMBER: NCT03508661 |
format | Online Article Text |
id | pubmed-6858260 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-68582602019-12-03 Scleroderma Patient-centered Intervention Network—Scleroderma Support group Leader EDucation (SPIN-SSLED) program: non-randomised feasibility trial Thombs, Brett D Dyas, Laura Pépin, Mia Aguila, Kylene Carrier, Marie-Eve Tao, Lydia Harb, Sami Malcarne, Vanessa L El-Baalbaki, Ghassan Peláez, Sandra Sauve, Maureen Hudson, Marie Platt, Robert W BMJ Open Patient-Centred Medicine OBJECTIVES: The Scleroderma Patient-centered Intervention Network—Scleroderma Support group Leader EDucation (SPIN-SSLED) Programme was designed to improve confidence and self-efficacy and to reduce burden for support group leaders. Objectives were to (1) evaluate feasibility of programme delivery, including required resources, management issues and scientific aspects (eg, performance of outcome measures) and (2) assess user satisfaction and identify any modifications needed to improve programme content or delivery based on participant feedback. DESIGN: Non-randomised feasibility trial. SETTING: North American patient organisations. PARTICIPANTS: Current support group leaders or potential new leaders referred by patient organisations. INTERVENTION: The programme included 13 modules delivered live via videoconference over 3 months (April to July 2018) in 60 to 90 min sessions. OUTCOME MEASURES: (1) Elements of feasibility, including enrolment and consent procedures, percentage of referred group leaders who consented to participate, session attendance and technical support requirements; (2) programme usability, understandability, organisation and clarity; (3) leader satisfaction with the programme and (4) planned trial outcome measures, including support group leader self-efficacy, burnout, emotional distress and physical function. RESULTS: All 12 referred potential participants consented to enrol, and 10 were included in two training groups of five participants each. Participants attended 95% of sessions. Required technical support was minimal, and videoconferencing technology functioned well. Overall programme satisfaction rating was 9.4/10. Mean item rating on the eight items of the Client Satisfaction Questionnaire-8 was 3.83 (1=low satisfaction; 4=high satisfaction). Pre-post scores on the Scleroderma Support Group Leader Self-efficacy Scale increased by 1.7 SDs (large effect); scores on burnout, emotional distress and physical function improved by 0.44, 0.38 and 0.45 SDs (moderate effects). CONCLUSION: The SPIN-SSLED Programme was feasibly delivered, including management, resource and scientific aspects. Participant satisfaction was high. The programme is ready to be tested in a full-scale randomised controlled trial. TRIAL REGISTRATION NUMBER: NCT03508661 BMJ Publishing Group 2019-11-11 /pmc/articles/PMC6858260/ /pubmed/31719073 http://dx.doi.org/10.1136/bmjopen-2019-029935 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Patient-Centred Medicine Thombs, Brett D Dyas, Laura Pépin, Mia Aguila, Kylene Carrier, Marie-Eve Tao, Lydia Harb, Sami Malcarne, Vanessa L El-Baalbaki, Ghassan Peláez, Sandra Sauve, Maureen Hudson, Marie Platt, Robert W Scleroderma Patient-centered Intervention Network—Scleroderma Support group Leader EDucation (SPIN-SSLED) program: non-randomised feasibility trial |
title | Scleroderma Patient-centered Intervention Network—Scleroderma Support group Leader EDucation (SPIN-SSLED) program: non-randomised feasibility trial |
title_full | Scleroderma Patient-centered Intervention Network—Scleroderma Support group Leader EDucation (SPIN-SSLED) program: non-randomised feasibility trial |
title_fullStr | Scleroderma Patient-centered Intervention Network—Scleroderma Support group Leader EDucation (SPIN-SSLED) program: non-randomised feasibility trial |
title_full_unstemmed | Scleroderma Patient-centered Intervention Network—Scleroderma Support group Leader EDucation (SPIN-SSLED) program: non-randomised feasibility trial |
title_short | Scleroderma Patient-centered Intervention Network—Scleroderma Support group Leader EDucation (SPIN-SSLED) program: non-randomised feasibility trial |
title_sort | scleroderma patient-centered intervention network—scleroderma support group leader education (spin-ssled) program: non-randomised feasibility trial |
topic | Patient-Centred Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858260/ https://www.ncbi.nlm.nih.gov/pubmed/31719073 http://dx.doi.org/10.1136/bmjopen-2019-029935 |
work_keys_str_mv | AT thombsbrettd sclerodermapatientcenteredinterventionnetworksclerodermasupportgroupleadereducationspinssledprogramnonrandomisedfeasibilitytrial AT dyaslaura sclerodermapatientcenteredinterventionnetworksclerodermasupportgroupleadereducationspinssledprogramnonrandomisedfeasibilitytrial AT pepinmia sclerodermapatientcenteredinterventionnetworksclerodermasupportgroupleadereducationspinssledprogramnonrandomisedfeasibilitytrial AT aguilakylene sclerodermapatientcenteredinterventionnetworksclerodermasupportgroupleadereducationspinssledprogramnonrandomisedfeasibilitytrial AT carriermarieeve sclerodermapatientcenteredinterventionnetworksclerodermasupportgroupleadereducationspinssledprogramnonrandomisedfeasibilitytrial AT taolydia sclerodermapatientcenteredinterventionnetworksclerodermasupportgroupleadereducationspinssledprogramnonrandomisedfeasibilitytrial AT harbsami sclerodermapatientcenteredinterventionnetworksclerodermasupportgroupleadereducationspinssledprogramnonrandomisedfeasibilitytrial AT malcarnevanessal sclerodermapatientcenteredinterventionnetworksclerodermasupportgroupleadereducationspinssledprogramnonrandomisedfeasibilitytrial AT elbaalbakighassan sclerodermapatientcenteredinterventionnetworksclerodermasupportgroupleadereducationspinssledprogramnonrandomisedfeasibilitytrial AT pelaezsandra sclerodermapatientcenteredinterventionnetworksclerodermasupportgroupleadereducationspinssledprogramnonrandomisedfeasibilitytrial AT sauvemaureen sclerodermapatientcenteredinterventionnetworksclerodermasupportgroupleadereducationspinssledprogramnonrandomisedfeasibilitytrial AT hudsonmarie sclerodermapatientcenteredinterventionnetworksclerodermasupportgroupleadereducationspinssledprogramnonrandomisedfeasibilitytrial AT plattrobertw sclerodermapatientcenteredinterventionnetworksclerodermasupportgroupleadereducationspinssledprogramnonrandomisedfeasibilitytrial AT sclerodermapatientcenteredinterventionnetworksclerodermasupportgroupleadereducationspinssledprogramnonrandomisedfeasibilitytrial |